Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
Sell
24
IONS Quote, Financials, Valuation and Earnings
Last price:
$28.62
Seasonality move
:
5.57%
Day range:
$28.16 - $28.97
52-week range:
$23.95 - $52.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.02x
P/B ratio:
7.67x
Volume:
1.5M
Avg. volume:
1.9M
1-year change:
-31.7%
Market cap:
$4.5B
Revenue:
$705.1M
EPS (TTM):
-$3.04
Analysts' Opinion
-
Consensus RatingIonis Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $57.43, Ionis Pharmaceuticals has an estimated upside of 102.34% from its current price of $28.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $37.00 representing -30.37% downside risk from its current price of $28.38.
Fair Value
-
According to the consensus of 20 analysts, Ionis Pharmaceuticals has 102.34% upside to fair value with a price target of $57.43 per share.
IONS vs. S&P 500
-
Over the past 5 trading days, Ionis Pharmaceuticals has overperformed the S&P 500 by 8.6% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ionis Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ionis Pharmaceuticals revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Ionis Pharmaceuticals reported revenues of $226.6M.
Earnings Growth
-
Ionis Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ionis Pharmaceuticals reported earnings per share of -$0.66.
Enterprise value:
3.5B
EV / Invested capital:
--
Price / LTM sales:
6.02x
EV / EBIT:
--
EV / Revenue:
4.92x
PEG ratio (5yr expected):
-0.50x
EV / Free cash flow:
-6.29x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$693.9M
Return On Assets:
-15.62%
Net Income Margin (TTM):
-64.37%
Return On Equity:
-103.27%
Return On Invested Capital:
-26.5%
Operating Margin:
-48.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $587.4M | $787.6M | $705.1M | $324.5M | $226.6M | |
| Gross Profit | $573.3M | $778.5M | $693.9M | $321.4M | $222.7M | |
| Operating Income | -$410.1M | -$353.8M | -$475.1M | -$6.1M | -$110.8M | |
| EBITDA | -$227.7M | -$234.5M | -$352.2M | $23.7M | -$80.5M | |
| Diluted EPS | -$1.90 | -$2.56 | -$3.04 | -$0.06 | -$0.66 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.1B | $2.3B | $2.2B | $2.6B | $2.6B | |
| Total Assets | $2.4B | $2.6B | $2.5B | $3B | $3B | |
| Current Liabilities | $598.9M | $240.6M | $311.6M | $448.1M | $309.3M | |
| Total Liabilities | $1.6B | $1.8B | $2B | $2.6B | $2.4B | |
| Total Equity | $743.3M | $771.7M | $572.9M | $386.7M | $588.4M | |
| Total Debt | $908.9M | $1.2B | $1.2B | $1.3B | $1.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$274.4M | -$307.5M | -$500.9M | $32.9M | -$116.1M | |
| Cash From Investing | -$262.6M | -$214.1M | -$134M | -$26.7M | $68.2M | |
| Cash From Financing | -$55.3M | $644.1M | $478.1M | $40.7M | -$44.1M | |
| Free Cash Flow | -$294.5M | -$335.5M | -$551.3M | $32.9M | -$144.2M | |
IONS
Sector
Market Cap
$4.5B
$35M
Price % of 52-Week High
54.22%
41.88%
Dividend Yield
0%
0%
Shareholder Yield
-9.38%
-0.91%
1-Year Price Total Return
-31.7%
-43.29%
Beta (5-Year)
0.287
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$27.45
200-day SMA
Sell
Level
$38.63
Bollinger Bands (100)
Sell
Level
30.49 - 35.97
Chaikin Money Flow
Sell
Level
-68.5M
20-day SMA
Sell
Level
$29.67
Relative Strength Index (RSI14)
Sell
Level
44.41
ADX Line
Sell
Level
30.83
Williams %R
Neutral
Level
-43.4949
50-day SMA
Sell
Level
$31.31
MACD (12, 26)
Sell
Level
-1.30
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
73.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.068)
Sell
CA Score
(Annual)
Level (-2.4873)
Buy
Beneish M-Score
(Annual)
Level (-3.351)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.5508)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Stock Forecast FAQ
In the current month, IONS has received 12 Buy ratings 8 Hold ratings, and 0 Sell ratings. The IONS average analyst price target in the past 3 months is $57.43.
-
Where Will Ionis Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ionis Pharmaceuticals share price will rise to $57.43 per share over the next 12 months.
-
What Do Analysts Say About Ionis Pharmaceuticals?
Analysts are divided on their view about Ionis Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ionis Pharmaceuticals is a Sell and believe this share price will drop from its current level to $37.00.
-
What Is Ionis Pharmaceuticals's Price Target?
The price target for Ionis Pharmaceuticals over the next 1-year time period is forecast to be $57.43 according to 20 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is IONS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ionis Pharmaceuticals is a Buy. 12 of 20 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IONS?
You can purchase shares of Ionis Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ionis Pharmaceuticals shares.
-
What Is The Ionis Pharmaceuticals Share Price Today?
Ionis Pharmaceuticals was last trading at $28.62 per share. This represents the most recent stock quote for Ionis Pharmaceuticals. Yesterday, Ionis Pharmaceuticals closed at $28.38 per share.
-
How To Buy Ionis Pharmaceuticals Stock Online?
In order to purchase Ionis Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will MSTY Go By 2030?
YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…
Will NVIDIA Stock Bounce Back?
After the wild market moves during February and March, investors…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
75
SKGR alert for Apr 13
SK Growth Opportunities [SKGR] is down 0% over the past day.
Sell
45
DSDVY alert for Apr 16
DSV AS [DSDVY] is down 2.26% over the past day.
Buy
76
PDEX alert for Apr 16
Pro-Dex [PDEX] is down 2.85% over the past day.
